Metraipolis › archive › dc_ae0e08affa8e
Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a… — Europe PMC PMID:42437411
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42437411
- DOI
- 10.1007/s00262-[numero omesso]-2
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-15T17:19:13.238Z
- SHA-256 of the archived text
7788fb5c2a07243cf401f28e58634510ffece2a03af8a32110b1091c702475b6- Stable URL of this page
https://metraipolis.com/documento/dc_ae0e08affa8e
How to cite
Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a… — Europe PMC PMID:42437411 — Europe PMC (en), https://europepmc.org/article/MED/42437411 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ae0e08affa8e (Metraipolis archive dc_ae0e08affa8e, sha256 7788fb5c2a07243cf401f28e58634510ffece2a03af8a32110b1091c702475b6)
BibTeX
@misc{dcae0e08affa8e,
title = {Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a… — Europe PMC PMID:42437411},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42437411},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ae0e08affa8e; sha256 7788fb5c2a07243cf401f28e58634510ffece2a03af8a32110b1091c702475b6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42437411. Agents can read the archived copy with the MCP tool read_document.